ReShape Lifesciences Has Received A Notice Of Allowance For Its U.S. Patent Application 17/572,387 titled "INTRAGASTRIC DEVICE (FOR TREATING OBESITY)"
Portfolio Pulse from Benzinga Newsdesk
ReShape Lifesciences has received a Notice of Allowance for its U.S. Patent Application 17/572,387 titled 'INTRAGASTRIC DEVICE (FOR TREATING OBESITY)'.
May 28, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ReShape Lifesciences has received a Notice of Allowance for its U.S. Patent Application for an intragastric device to treat obesity.
The Notice of Allowance for the patent application indicates that ReShape Lifesciences is likely to secure intellectual property protection for its intragastric device, which could enhance its product portfolio and market position in obesity treatment. This development is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100